Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sunitinib - Pfizer

Drug Profile

Sunitinib - Pfizer

Alternative Names: PHA-290940; PHA-290940AD; PNU-290940; PNU-290940AD; SU-011248; SU-11248; SU-11428; Sunitinib malate; Sutent

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Australasian Sarcoma Study Group; Cancer Research UK; Case Comprehensive Cancer Center; Clatterbridge Cancer Centre NHS Foundation Trust; Dana-Farber Cancer Institute; Hoosier Cancer Research Network; Korean Urological Oncology Society; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Ohio State University; Pfizer; University of Michigan Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center; US Oncology Research
  • Class Amides; Antineoplastics; Ethylamines; Eye disorder therapies; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Colony stimulating factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Gastrointestinal stromal tumours; Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastrointestinal stromal tumours; Pancreatic cancer; Renal cell carcinoma
  • Phase II Alveolar soft part sarcoma; Bladder cancer; Neuroendocrine tumours; Oesophageal cancer; Phaeochromocytoma; Prostate cancer; Thyroid cancer; Uveal melanoma
  • Phase I/II Soft tissue sarcoma
  • No development reported Germ cell cancer; Liver cancer
  • Discontinued Acral lentiginous melanoma; Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Urogenital cancer

Most Recent Events

  • 01 Nov 2022 Efficacy data in Prostrate cancer presented at 47th European Society for Medical Oncology Congress (ESMO-2022)
  • 06 Jun 2022 Phase-II clinical trials in Alveolar soft part sarcoma (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (PO) in July 2011 (NCT01391962)
  • 23 May 2022 Pfizer in collaboration with Assistance Publique - Hôpitaux de Paris terminates a phase III CARMENA trial in Renal cell carcinoma (Metastatic-disease, Late-stage disease, Monotherapy) in France (PO) due to slow recruitment, and the results from interim analysis were sufficient to meet the objectives of the trial (NCT00930033)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top